Research Analysts Set Expectations for COGT Q1 EarningsMarket Beat·2 days ago, 06:12 AMCOGT+4.02%GS-C-0.10%
Analyst Reiterates Buy on Cogent Biosciences, Maintains $55 Price Target Amid Late-Stage Pipeline and Strong Cash PositionTip Ranks·Aug 19 at 11:45 AMCOGT+4.02%
Wedbush Reaffirms Their Buy Rating on Cogent Biosciences (COGT)Tip Ranks·Aug 11 at 08:55 AMCOGT+4.02%
Regulatory Catalysts and Launch Readiness for Bezuclasitinib Underpin Sam Slutsky’s Buy Rating on Cogent BiosciencesTip Ranks·Aug 10 at 05:45 PMCOGT+4.02%
Cogent Biosciences files for USD 400 million at-the-market stock offeringPUBT·Aug 10 at 04:20 PMCOGT+4.02%
If You Invested $100 In Advanced Energy Indus Stock 20 Years Ago, You Would Have This Much Todaybenzinga_article·Aug 7 at 03:30 PMAEIS-2.32%
Cogent Biosciences submits FDA NDA for bezuclastinib in advanced systemic mastocytosisPUBT·Jun 30 at 07:02 AMCOGT+4.02%
Why Cogent Biosciences (COGT) Is Up 6.7% After Russell Index Removal Reshapes Its Investor BaseSimplywall·Jun 29 at 11:11 PMCOGT+4.02%
H.C. Wainwright Sticks to Its Buy Rating for Cogent Biosciences (COGT)Tip Ranks·Jun 17 at 08:35 AMCOGT+4.02%
